Aliza Brown
Concepts (242)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 12 | 2020 | 526 | 2.140 |
Why?
| Thrombolytic Therapy | 8 | 2020 | 127 | 1.220 |
Why?
| Tissue Plasminogen Activator | 9 | 2020 | 124 | 1.190 |
Why?
| Endarterectomy, Carotid | 9 | 2011 | 59 | 0.940 |
Why?
| Health Services Misuse | 1 | 2020 | 15 | 0.750 |
Why?
| Tunica Intima | 8 | 2011 | 52 | 0.730 |
Why?
| Fibrinolytic Agents | 7 | 2020 | 139 | 0.730 |
Why?
| Homocysteine | 7 | 2011 | 126 | 0.690 |
Why?
| Disease Models, Animal | 12 | 2015 | 1651 | 0.590 |
Why?
| Microbubbles | 3 | 2011 | 34 | 0.590 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.580 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.570 |
Why?
| Emergency Service, Hospital | 2 | 2020 | 540 | 0.570 |
Why?
| Emergency Medical Technicians | 1 | 2016 | 11 | 0.570 |
Why?
| Carotid Arteries | 6 | 2010 | 82 | 0.570 |
Why?
| Fluorocarbons | 4 | 2019 | 52 | 0.530 |
Why?
| Emergency Medical Services | 1 | 2016 | 126 | 0.520 |
Why?
| Ultrasonic Therapy | 3 | 2011 | 40 | 0.510 |
Why?
| Acetylcysteine | 2 | 2011 | 118 | 0.490 |
Why?
| Acetaminophen | 3 | 2011 | 350 | 0.480 |
Why?
| Quality Improvement | 1 | 2016 | 245 | 0.470 |
Why?
| Cerebral Hemorrhage | 3 | 2015 | 105 | 0.420 |
Why?
| Brain Ischemia | 4 | 2019 | 169 | 0.400 |
Why?
| Rural Population | 1 | 2016 | 597 | 0.400 |
Why?
| Intracranial Embolism | 2 | 2012 | 28 | 0.400 |
Why?
| Liver Failure, Acute | 1 | 2011 | 64 | 0.390 |
Why?
| Rabbits | 10 | 2016 | 425 | 0.380 |
Why?
| Carotid Stenosis | 4 | 2011 | 61 | 0.320 |
Why?
| Animals | 26 | 2016 | 14402 | 0.290 |
Why?
| Neuroprotective Agents | 2 | 2019 | 125 | 0.280 |
Why?
| Time Factors | 11 | 2020 | 3207 | 0.270 |
Why?
| Insulin Resistance | 2 | 2010 | 299 | 0.270 |
Why?
| Magnetic Resonance Imaging | 2 | 2014 | 1616 | 0.260 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2006 | 179 | 0.220 |
Why?
| Brain | 1 | 2010 | 1391 | 0.200 |
Why?
| Rats | 12 | 2011 | 3417 | 0.190 |
Why?
| United States | 4 | 2020 | 5204 | 0.190 |
Why?
| Rats, Sprague-Dawley | 9 | 2011 | 1664 | 0.190 |
Why?
| Hyperplasia | 8 | 2011 | 107 | 0.190 |
Why?
| Conflict of Interest | 1 | 2020 | 24 | 0.180 |
Why?
| Thrombectomy | 1 | 2020 | 68 | 0.180 |
Why?
| Disease Outbreaks | 1 | 2020 | 124 | 0.170 |
Why?
| Fabry Disease | 1 | 2019 | 9 | 0.170 |
Why?
| Angiography, Digital Subtraction | 2 | 2011 | 33 | 0.170 |
Why?
| Enzyme Replacement Therapy | 1 | 2019 | 19 | 0.170 |
Why?
| Male | 21 | 2019 | 27335 | 0.170 |
Why?
| Carotid Artery, Common | 2 | 2011 | 43 | 0.170 |
Why?
| Ischemic Attack, Transient | 1 | 2019 | 60 | 0.170 |
Why?
| Cardiology | 1 | 2020 | 105 | 0.160 |
Why?
| Cerebral Angiography | 3 | 2012 | 106 | 0.160 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2004 | 53 | 0.140 |
Why?
| Infarction, Anterior Cerebral Artery | 1 | 2015 | 2 | 0.130 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2015 | 44 | 0.130 |
Why?
| Ticlopidine | 2 | 2006 | 57 | 0.130 |
Why?
| Pandemics | 1 | 2020 | 593 | 0.130 |
Why?
| Antidotes | 2 | 2011 | 33 | 0.130 |
Why?
| Salivary Proteins and Peptides | 2 | 2004 | 9 | 0.120 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2005 | 121 | 0.120 |
Why?
| L-Lactate Dehydrogenase | 1 | 2014 | 79 | 0.120 |
Why?
| Humans | 12 | 2020 | 54304 | 0.120 |
Why?
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 45 | 0.120 |
Why?
| Fractures, Compression | 1 | 2013 | 19 | 0.110 |
Why?
| Fractures, Spontaneous | 1 | 2013 | 19 | 0.110 |
Why?
| Models, Animal | 4 | 2011 | 254 | 0.110 |
Why?
| Telemedicine | 1 | 2019 | 457 | 0.110 |
Why?
| Spine | 1 | 2013 | 112 | 0.110 |
Why?
| Treatment Outcome | 5 | 2019 | 5609 | 0.100 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.100 |
Why?
| Echinomycin | 1 | 2011 | 7 | 0.100 |
Why?
| Carotid Artery Injuries | 1 | 2011 | 14 | 0.100 |
Why?
| Statistics as Topic | 1 | 2011 | 100 | 0.100 |
Why?
| Analysis of Variance | 2 | 2011 | 634 | 0.100 |
Why?
| Circle of Willis | 1 | 2011 | 4 | 0.100 |
Why?
| Cerebral Infarction | 1 | 2011 | 32 | 0.100 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2011 | 26 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2011 | 922 | 0.100 |
Why?
| Intracranial Hemorrhages | 1 | 2011 | 41 | 0.100 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2010 | 20 | 0.100 |
Why?
| Acarbose | 1 | 2010 | 2 | 0.100 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2000 | 17 | 0.100 |
Why?
| Indocyanine Green | 1 | 2010 | 39 | 0.100 |
Why?
| Analgesics, Non-Narcotic | 1 | 2011 | 140 | 0.090 |
Why?
| Estradiol | 1 | 2011 | 219 | 0.090 |
Why?
| Hepatocytes | 1 | 2011 | 214 | 0.090 |
Why?
| Trachea | 1 | 2000 | 51 | 0.090 |
Why?
| Subarachnoid Hemorrhage | 1 | 2010 | 65 | 0.090 |
Why?
| Ultrasonography, Interventional | 1 | 2010 | 146 | 0.090 |
Why?
| Hypoglycemic Agents | 1 | 2010 | 177 | 0.080 |
Why?
| Female | 11 | 2019 | 28457 | 0.080 |
Why?
| Radiography | 1 | 2010 | 526 | 0.080 |
Why?
| Arkansas | 3 | 2019 | 2097 | 0.080 |
Why?
| Dietary Sucrose | 2 | 2010 | 14 | 0.080 |
Why?
| Glucocorticoids | 1 | 2000 | 234 | 0.080 |
Why?
| Cystathionine beta-Synthase | 2 | 2004 | 13 | 0.080 |
Why?
| Dexamethasone | 1 | 2000 | 435 | 0.080 |
Why?
| Ketorolac Tromethamine | 1 | 2007 | 2 | 0.080 |
Why?
| Myocytes, Smooth Muscle | 2 | 2005 | 92 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2011 | 1294 | 0.080 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2007 | 44 | 0.080 |
Why?
| Cerebral Veins | 1 | 2007 | 16 | 0.070 |
Why?
| Recovery of Function | 2 | 2019 | 222 | 0.070 |
Why?
| Cerebral Arteries | 1 | 2007 | 37 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2019 | 401 | 0.070 |
Why?
| Random Allocation | 3 | 2015 | 308 | 0.070 |
Why?
| Mice | 3 | 2011 | 6428 | 0.070 |
Why?
| Pravastatin | 1 | 2006 | 16 | 0.070 |
Why?
| Middle Aged | 6 | 2019 | 13076 | 0.070 |
Why?
| Insulin | 2 | 2010 | 510 | 0.070 |
Why?
| Antioxidants | 1 | 2007 | 297 | 0.060 |
Why?
| Antineoplastic Agents | 1 | 2014 | 1300 | 0.060 |
Why?
| Constriction | 1 | 2004 | 9 | 0.060 |
Why?
| Smoke | 1 | 2004 | 21 | 0.060 |
Why?
| Platelet Aggregation | 1 | 2005 | 82 | 0.060 |
Why?
| Blood Platelets | 2 | 2006 | 268 | 0.060 |
Why?
| Muscle, Smooth, Vascular | 1 | 2005 | 140 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 150 | 0.060 |
Why?
| Liver | 1 | 2010 | 1226 | 0.060 |
Why?
| Databases, Factual | 2 | 2020 | 683 | 0.060 |
Why?
| Cell Division | 1 | 2005 | 330 | 0.060 |
Why?
| Aged | 5 | 2019 | 10054 | 0.060 |
Why?
| Emulsions | 2 | 2015 | 27 | 0.060 |
Why?
| Cystathionine gamma-Lyase | 1 | 2003 | 4 | 0.060 |
Why?
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 12 | 0.060 |
Why?
| Neoplasms | 1 | 2014 | 1321 | 0.060 |
Why?
| Postoperative Period | 1 | 2004 | 189 | 0.060 |
Why?
| Saphenous Vein | 1 | 2004 | 75 | 0.060 |
Why?
| Endothelium, Vascular | 1 | 2005 | 288 | 0.060 |
Why?
| Lower Extremity | 1 | 2004 | 103 | 0.060 |
Why?
| Arterial Occlusive Diseases | 1 | 2004 | 92 | 0.060 |
Why?
| Dietary Carbohydrates | 1 | 2003 | 90 | 0.060 |
Why?
| Dietary Fats | 1 | 2003 | 138 | 0.050 |
Why?
| Diet | 2 | 2005 | 584 | 0.050 |
Why?
| Folic Acid | 1 | 2003 | 139 | 0.050 |
Why?
| Preoperative Care | 1 | 2004 | 184 | 0.050 |
Why?
| Oxidative Stress | 1 | 2007 | 956 | 0.050 |
Why?
| Collagen | 1 | 2003 | 223 | 0.050 |
Why?
| Renal Dialysis | 1 | 2003 | 193 | 0.050 |
Why?
| Retrospective Studies | 3 | 2019 | 6462 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 3 | 2011 | 1476 | 0.050 |
Why?
| Health Care Sector | 1 | 2020 | 17 | 0.050 |
Why?
| Drug Industry | 1 | 2020 | 40 | 0.050 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| alpha-Galactosidase | 1 | 2019 | 9 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2018 | 1222 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 75 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 103 | 0.040 |
Why?
| Multiple Myeloma | 1 | 2013 | 3049 | 0.040 |
Why?
| Cell Count | 2 | 2005 | 181 | 0.040 |
Why?
| Double-Blind Method | 1 | 2019 | 742 | 0.040 |
Why?
| Glutamates | 1 | 2016 | 22 | 0.040 |
Why?
| Referral and Consultation | 1 | 2019 | 307 | 0.040 |
Why?
| Blotting, Western | 2 | 2005 | 684 | 0.040 |
Why?
| Angiography | 1 | 2016 | 148 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2011 | 1064 | 0.030 |
Why?
| Single-Blind Method | 1 | 2015 | 120 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2015 | 231 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 158 | 0.030 |
Why?
| Blood Chemical Analysis | 1 | 2014 | 34 | 0.030 |
Why?
| Reperfusion Injury | 1 | 2015 | 117 | 0.030 |
Why?
| Adult | 3 | 2014 | 14189 | 0.030 |
Why?
| Infusion Pumps, Implantable | 1 | 2011 | 14 | 0.030 |
Why?
| Angioplasty | 1 | 2011 | 26 | 0.030 |
Why?
| Immunohistochemistry | 2 | 2005 | 1090 | 0.030 |
Why?
| Hyperhomocysteinemia | 1 | 2011 | 30 | 0.030 |
Why?
| Jugular Veins | 1 | 2011 | 35 | 0.030 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2011 | 82 | 0.030 |
Why?
| Estrogen Replacement Therapy | 1 | 2011 | 41 | 0.030 |
Why?
| Liver Regeneration | 1 | 2011 | 57 | 0.030 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 60 | 0.030 |
Why?
| Ovariectomy | 1 | 2011 | 127 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 230 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2011 | 318 | 0.020 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2000 | 4 | 0.020 |
Why?
| Ultrasonography, Doppler, Pulsed | 1 | 2010 | 2 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2010 | 148 | 0.020 |
Why?
| Isoproterenol | 1 | 2000 | 52 | 0.020 |
Why?
| Adrenergic beta-Agonists | 1 | 2000 | 43 | 0.020 |
Why?
| Phlebography | 1 | 2010 | 70 | 0.020 |
Why?
| Luciferases | 1 | 2000 | 57 | 0.020 |
Why?
| Coloring Agents | 1 | 2010 | 84 | 0.020 |
Why?
| Epithelium | 1 | 2000 | 68 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2011 | 233 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 2010 | 199 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2010 | 151 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2010 | 121 | 0.020 |
Why?
| Cyclic AMP | 1 | 2000 | 106 | 0.020 |
Why?
| Blood Flow Velocity | 1 | 2010 | 114 | 0.020 |
Why?
| Propranolol | 1 | 2000 | 78 | 0.020 |
Why?
| Norepinephrine | 1 | 2000 | 119 | 0.020 |
Why?
| Epinephrine | 1 | 2000 | 97 | 0.020 |
Why?
| Transfection | 1 | 2000 | 399 | 0.020 |
Why?
| Cell Membrane | 1 | 2000 | 279 | 0.020 |
Why?
| Ultrasonography | 1 | 2011 | 486 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2000 | 418 | 0.020 |
Why?
| DNA | 1 | 2011 | 581 | 0.020 |
Why?
| Malondialdehyde | 1 | 2007 | 63 | 0.020 |
Why?
| Platelet Activation | 1 | 2007 | 50 | 0.020 |
Why?
| Blood Glucose | 1 | 2010 | 487 | 0.020 |
Why?
| Triiodobenzoic Acids | 1 | 2007 | 10 | 0.020 |
Why?
| Cell Line | 1 | 2000 | 1152 | 0.020 |
Why?
| Glutathione | 1 | 2007 | 330 | 0.020 |
Why?
| Drug Combinations | 1 | 2006 | 128 | 0.020 |
Why?
| Dizocilpine Maleate | 1 | 2005 | 16 | 0.020 |
Why?
| Cholesterol | 1 | 2006 | 150 | 0.020 |
Why?
| Contrast Media | 1 | 2007 | 221 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2013 | 3430 | 0.020 |
Why?
| Interleukin-1 | 1 | 2005 | 107 | 0.020 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 93 | 0.020 |
Why?
| Homocystine | 1 | 2004 | 7 | 0.020 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2005 | 51 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 145 | 0.020 |
Why?
| Platelet Function Tests | 1 | 2004 | 20 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2005 | 112 | 0.020 |
Why?
| Aorta, Thoracic | 1 | 2005 | 89 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2006 | 159 | 0.020 |
Why?
| Cotinine | 1 | 2004 | 23 | 0.020 |
Why?
| Probability | 1 | 2004 | 177 | 0.020 |
Why?
| Cell Movement | 1 | 2005 | 271 | 0.020 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2004 | 25 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2004 | 195 | 0.020 |
Why?
| Reference Values | 1 | 2004 | 353 | 0.020 |
Why?
| RNA | 1 | 2005 | 202 | 0.010 |
Why?
| Arginine | 1 | 2005 | 182 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2007 | 1083 | 0.010 |
Why?
| Platelet Adhesiveness | 1 | 2003 | 13 | 0.010 |
Why?
| Elastin | 1 | 2003 | 22 | 0.010 |
Why?
| Polytetrafluoroethylene | 1 | 2003 | 36 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 674 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 2003 | 72 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 4313 | 0.010 |
Why?
| Vascular Patency | 1 | 2003 | 92 | 0.010 |
Why?
| Signal Transduction | 1 | 2000 | 1751 | 0.010 |
Why?
| Dogs | 1 | 2003 | 216 | 0.010 |
Why?
| Nitric Oxide | 1 | 2005 | 298 | 0.010 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.010 |
Why?
| Graft Occlusion, Vascular | 1 | 2003 | 86 | 0.010 |
Why?
| Gene Expression | 1 | 2005 | 664 | 0.010 |
Why?
| RNA, Messenger | 1 | 2005 | 1203 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6896 | 0.010 |
Why?
| Cell Proliferation | 1 | 2005 | 1097 | 0.010 |
Why?
| Cells, Cultured | 1 | 2005 | 1737 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 825 | 0.010 |
Why?
|
|
Brown's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|